Ascendia

  MARKET NEWS

Anavex’s Phase 2b/3 Trial of Blarcamesine in Patients With Alzheimer’s Disease Shows Robust Clinical Efficacy & Slows Neurodegeneration
Evoke Pharma Receives Notice of Allowance from USPTO for First & Only FDA-Approved Nasal Formulation of Metoclopramide Commercially Available in the US
KBI Biopharma Expands Global Portfolio With Launch of SUREmAb for Faster Monoclonal Antibody Development & Manufacturing
Salipro Biotech Enters Research Collaboration With Sumitomo Pharma to Advance Drug Discovery Program
Spinogenix Awarded $3-Million NIH Grant to Support Continued Development of the First Synaptic Regenerative Therapeutic for Alzheimer’s Disease
Lisata Therapeutics Announces First Patient Treated in BOLSTER Trial Novel Tumor-Targeting & Penetrating Peptide in Patients With Advanced Solid Tumors

  FEATURED EDITORIAL

  COMPANY PROFILE

Fortis Life Sciences offers world-class reagents, tools, materials, and custom services with a best-in-class customer experience for our customers in the biopharma industry. Through our brand nanoComposix, we provide precisely engineered and highly characterized nanomaterials to a global customer base. nanoComposix is an ISO 13485 (2016)-Certified*, FDA-registered developer and contract manufacturer with a nanomaterial product portfolio containing hundreds of variants engineered to address the unique challenges presented by our customers. Our products and CDMO services are backed by technical teams with extensive expertise in nanotechnology, biology, chemistry, physics, and optics. Click here for more.

  EXCLUSIVE ONLINE CONTENT

New Collaboration With Stevanato Group to Elevate mRNA Production With Nfinity Platform

New Collaboration With Stevanato Group to Elevate mRNA Production With Nfinity Platform

Quantoom Biosciences recently announced a new collaboration with Stevanato Group, a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life science industries, with the goal of….

First Wave BioPharma Announces Exclusive Global License Agreement for Capeserod From Sanofi

First Wave BioPharma Announces Exclusive Global License Agreement for Capeserod From Sanofi

First Wave to develop and repurpose Capeserod for gastrointestinal (GI) indications based on AI-empowered analyses, expanding the company’s GI-focused pipeline….

Rencofilstat Produces Positive Outcomes in Translational Study on Idiopathic Pulmonary Fibrosis

Rencofilstat Produces Positive Outcomes in Translational Study on Idiopathic Pulmonary Fibrosis

Hepion Pharmaceuticals, Inc. recently announced positive results from a translational research study in which Hepion’s lead drug candidate, rencofilstat, was administered to diseased human lung tissue from….

Curia Supports Replicate Bioscience’s Phase 1 Clinical Trial of Novel Next-Generation RNA Vaccine

Curia Supports Replicate Bioscience’s Phase 1 Clinical Trial of Novel Next-Generation RNA Vaccine

Supply of drug substance manufactured under cGMP supports first-in-human clinical study for RBI-4000 novel self-replicating RNA (srRNA)….

  WHITEPAPERS & WEBINARS

 

WEBINAR - Impact of Process Re-design on Sustainability in Pharmaceutical Small Molecule Manufacturing

WEBINAR - Impact of Process Re-design on Sustainability in Pharmaceutical Small Molecule Manufacturing

Join us for an upcoming webinar that delves into a crucial issue in the pharmaceutical industry. Recent research has revealed a surprising fact: the pharmaceutical sector has a larger carbon footprint than even the automotive industry, especially when we consider the entire supply chain’s impact on

WEBINAR - Beyond the Lab: Unleashing the Potential of In Silico Modeling in Drug Product Formulation

WEBINAR - Beyond the Lab: Unleashing the Potential of In Silico Modeling in Drug Product Formulation

In this webinar you will learn how digital chemistry tools facilitate rapid screening of formulation parameters, aiding in the identification of optimal drug delivery systems, excipient selection, and dosage forms….

  WHITEPAPERS & WEBINARS

WHITEPAPER - Streamline Early-Stage Development to Reach the Clinic Faster

WHITEPAPER - Streamline Early-Stage Development to Reach the Clinic Faster

Early-stage development is critical to shortening your product’s timelines while establishing a solid foundation for clinical trials. In this insightful article from Dr. Srinivasan Shanmugam, Adare’s Executive Director of Pharmaceutical Sciences, learn what’s needed to make your product’s early-stage development …

WHITEPAPER - Accelerate Preclinical Developments & Improve Oral Bioavailability With Lipid-Based Formulation & Encapsulation Technology Combination

WHITEPAPER - Accelerate Preclinical Developments & Improve Oral Bioavailability With Lipid-Based Formulation & Encapsulation Technology Combination

Owing its convenience, oral administration is patients’ preferred route of delivery for therapeutic molecules. However, most New Chemical Entities (NCE) exhibit physico-chemical properties limiting their absorption in the gastro-intestinal (GI) tract. Indeed, according to Pharmacircle data from March 2022, almost …

WHITEPAPER - Improving API Solubility by Salt & Cocrystal Formation

WHITEPAPER - Improving API Solubility by Salt & Cocrystal Formation

Ensuring sufficient solubility is critical to the success of small molecule drugs. An active pharmaceutical ingredient (API) must be absorbed by the body and enter the systemic circulation to deliver the desired therapeutic effect. Many APIs, however, suffer from low …

WHITEPAPER - Effect of Excipient Choices on Topical Formulations & Manufacturing Processes

WHITEPAPER - Effect of Excipient Choices on Topical Formulations & Manufacturing Processes

In this whitepaper, we review the effect of excipient choice on the process of manufacturing topical products. The effect of the following excipient types will be discussed: surface active agents, preservatives, polymer choice and skin penetration enhancers.

Considerations include the …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

September 27 – Analytical Testing
October 4 – Formulation Development